Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more
Entera Bio Ltd (ENTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.180x
Based on the latest financial reports, Entera Bio Ltd (ENTX) has a cash flow conversion efficiency ratio of -0.180x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.74 Million) by net assets ($15.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Entera Bio Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Entera Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entera Bio Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Regina Miracle International (Holdings) Limited
F:RMT
|
0.156x |
|
Jiangxi Chen Guang New Materials Co Ltd
SHG:605399
|
-0.014x |
|
Finder Energy Holdings Ltd
AU:FDR
|
-0.630x |
|
Ihlas Gayrimenkul Proje Gelistirme ve Ticaret AS
IS:IHLGM
|
-0.001x |
|
Siamese Asset Public Company Limited
BK:SA
|
-0.001x |
|
Hwacheon Machi
KO:010660
|
-0.024x |
|
Expensify Inc
NASDAQ:EXFY
|
0.031x |
|
Mopas Marketcilik Gida
IS:MOPAS
|
N/A |
Annual Cash Flow Conversion Efficiency for Entera Bio Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Entera Bio Ltd from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.08 Million | $-6.82 Million | -0.844x | -19.89% |
| 2023-12-31 | $10.39 Million | $-7.31 Million | -0.704x | +33.81% |
| 2022-12-31 | $11.75 Million | $-12.50 Million | -1.063x | -164.76% |
| 2021-12-31 | $22.57 Million | $-9.06 Million | -0.402x | +71.43% |
| 2020-12-31 | $7.51 Million | $-10.56 Million | -1.406x | -87.86% |
| 2019-12-31 | $11.92 Million | $-8.92 Million | -0.748x | +22.73% |
| 2018-12-31 | $10.12 Million | $-9.80 Million | -0.968x | -775.20% |
| 2017-12-31 | $-31.56 Million | $-4.53 Million | 0.143x | +15.24% |
| 2016-12-31 | $-25.25 Million | $-3.14 Million | 0.124x | -8.53% |
| 2015-12-31 | $-25.69 Million | $-3.50 Million | 0.136x | -- |